Competitive Rivalry

Novo Nordisk competes in a duopoly-like obesity and diabetes market with Eli Lilly, which keeps pricing power meaningful but limits peer-leading margin expansion.

High clinical differentiation in GLP-1 therapies supports premium pricing, yet Lilly’s rapid share gains and capacity buildout intensify rivalry versus other global peers.

Patent-protected branded biologics reduce direct generic rivalry, but therapeutic competition shifts to efficacy, tolerability, and supply availability, constraining industry-wide pricing discipline.

Broader diabetes portfolios and adjacent cardiometabolic franchises create cross-category competition, but Novo’s scale and brand recognition still preserve stronger economics than most global pharma peers.

Threat Of New Entrants

Large-scale biologics development, regulatory approval, and global commercialization create high entry barriers, making meaningful new entrants unlikely versus established global peers.

Manufacturing complexity for peptide and injectable supply chains raises capital and quality hurdles, which protects incumbent pricing power and margins over a 2–5 year horizon.

Patent estates and clinical evidence requirements delay entry into obesity and diabetes markets, so competitive pressure is more likely from incumbents than from startups.

Even where new modalities emerge, reimbursement access and physician adoption favor proven brands, limiting the ability of entrants to erode Novo’s structural position quickly.

Bargaining Power Of Suppliers

Specialized API, fill-finish, and device inputs can tighten supply economics, but Novo’s scale and long-term sourcing reduce supplier leverage versus smaller peers.

Capacity constraints in biologics manufacturing can raise input costs across the industry, yet they are more likely to affect growth timing than durable margin structure.

Dependence on a limited set of high-specification suppliers creates some vulnerability, but the company’s global footprint provides better procurement leverage than most pharma peers.

Supplier power is not negligible because quality and regulatory standards narrow the vendor base, but it remains a manageable constraint rather than a dominant margin driver.

Bargaining Power Of Buyers

Large U.S. payers and pharmacy benefit managers can extract rebates on GLP-1 access, materially reducing realized pricing versus list prices for all branded peers.

Coverage decisions and step-therapy controls make buyer power especially relevant in obesity, where demand is strong but reimbursement remains the key gatekeeper.

Novo’s differentiated efficacy supports inclusion, yet Lilly’s competing portfolio gives buyers credible alternatives, limiting Novo’s ability to defend net pricing unilaterally.

Outside the U.S., single-payer and tender-based systems compress pricing further, so buyer power is structurally stronger than in many specialty-pharma categories.

Threat Of Substitutes

For obesity and diabetes, substitutes include older generics, lifestyle intervention, bariatric surgery, and emerging oral or next-generation incretin therapies, but none fully match current branded efficacy.

The strongest substitution risk comes from Lilly’s competing incretin franchise and future oral options, which can shift demand without requiring a true therapeutic class exit.

In diabetes, broad treatment pathways reduce switching costs, yet superior weight-loss and cardiometabolic outcomes keep Novo’s current products relatively insulated versus peers.

Substitution pressure exists, but it is constrained by clinical superiority and reimbursement economics, preserving better pricing power than in commoditized pharma segments.

Overall Score

Novo Nordisk benefits from high structural barriers, strong clinical differentiation, and limited new-entry risk, but rivalry with Lilly and payer pressure cap absolute pricing power versus top peers.